Analysis of new molecular entity trends from 2006 to 2015 in Japan
Authors:
- 5 June 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Generic Medicines
- Vol. 16 (4) , 161-170
Abstract
Japan is one of the largest pharmaceutical markets in the world, and as such, pharmaceutical companies are intensively conducting research and development of new drugs in Japan. However, information on Japanese pharmaceutical market profiles is limited. In this context, we elucidated the market characteristics and trends of new molecular entities approved between 2006 and 2015 in Japan. Among antineoplastic and immunomodulating agents, the highest number was first approved in the United States, and for nervous system drugs, the highest number was first approved in Europe. The alimentary tract and metabolism and the musculoskeletal system were the therapeutic areas for which the most drugs were approved for the first time in Japan. Most of the musculoskeletal system drugs were developed by Japanese companies, and most of the antineoplastic and immunomodulating agents were developed outside of Japan. Using various performance indexes, such as market forecasts and significance of clinical benefits, we determined that the number of new molecular entities and market size increased and the number of drugs with significant clinical benefits decreased. These results suggest that new molecular entity innovation by Japanese companies has been decreasing and the government’s comparative method for pricing does not work well in Japan.Keywords
This publication has 25 references indexed in Scilit:
- The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classesJournal of Generic Medicines, 2017
- Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery PricesTherapeutic Innovation & Regulatory Science, 2017
- An Empirical Study of the Prescription Pattern of Drugs for Hematological Malignancies in Japan from 2010–2014Biological and Pharmaceutical Bulletin, 2017
- The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United StatesTherapeutic Innovation & Regulatory Science, 2017
- Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing SystemTherapeutic Innovation & Regulatory Science, 2016
- Regulatory approval pathways for anticancer drugs in Japan, the EU and the USInternational Journal of Hematology, 2016
- Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and GermanyTherapeutic Innovation & Regulatory Science, 2016
- Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic AreaTherapeutic Innovation & Regulatory Science, 2016
- Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in JapanTherapeutic Innovation & Regulatory Science, 2016
- Defining “Innovativeness” in Drug Development: A Systematic ReviewClinical Pharmacology & Therapeutics, 2013